Heart Failure: Evolving Treatment Choices and New Guidance (Regional)

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
September 19, 2022 5:30 PM - 6:30 PM PT
October 11, 2022 5:30 PM - 6:30 PM PT
November 17, 2022 6:00 PM - 7:00 PM CT
Credit Type(s):
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2021. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF there are currently no approved therapies although there are agents in phase 3 clinical trials.

Heart Failure: Evolving Treatment Choices and New Guidance will address the rapidly shifting HF management paradigm, providing information about the most recent evidence-based recommendations for managing HFrEF, newer approved agents, and those agents for which approval is anticipated soon, as well as agents in late-stage investigation for the management of HFpEF.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Merck & Co, Inc.

RELATED COURSES

Managing Heart Disease in Type 2 Diabetes: Incorporating Diabetes Drugs into the Management of Cardiometabolic Disease (Regionals)

Learn More

Improving the Outlook for Heart Failure: Incorporating New Agents and New Guidance

Learn More

Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy